ntla-2001
Gene therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Nov 5, 2020 (NCT04601051)
Timeline
Indications
Studied for
- Amyloid Neuropathies · Phase 3
- Amyloid Neuropathies, Familial · Phase 3
- Amyloidosis · Phase 3
- Amyloidosis, Familial · Phase 3
- Cardiomyopathies · Phase 3
- Genetic Diseases, Inborn · Phase 3
- Heredodegenerative Disorders, Nervous System · Phase 3
- Metabolic Diseases · Phase 3
- Metabolism, Inborn Errors · Phase 3
- Nervous System Diseases · Phase 3
- Neurodegenerative Diseases · Phase 3
- Neuromuscular Diseases · Phase 3
- Peripheral Nervous System Diseases · Phase 3
- Polyneuropathies · Phase 3
- Polyradiculoneuropathy · Phase 1
Mechanism of action
- TransthyretinINHIBITOR
TTR inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06672237 | Phase 3 | Nov 30, 2024 | Intellia Therapeutics, Regeneron |
| NCT06128629 | Phase 3 | Dec 31, 2023 | Intellia Therapeutics, Regeneron |
| NCT04601051 | Phase 1 | Nov 5, 2020 | Intellia Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Intellia Therapeutics | For profit | 3 | 3 | 2 | 2020 |
| Regeneron | For profit | 2 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1